Effects of the in ovo injection of a commercial coccidiosis vaccine on the hatchability and hatching chick quality variables of Ross × Ross 708 broilers were examined. Four treatment (TRT) groups were represented on each of 7 replicate tray levels of a single-stage incubator (28 TRT-replicate groups). Each TRT-replicate contained 63 eggs (1,764 total eggs). On d 18.5 of incubation, eggs were subjected to one of 4 TRT using a commercial multi-egg injector. Three control groups (non-injected, dry-punch, and diluentinjected) and one TRT group (injected with diluent containing Inovocox EM1 vaccine) were used. On d 18.5 of incubation, the site of injection and stage of embryo development were determined. On d 21.5 of incubation (d zero post hatch), hatchability of injected eggs (HI), chick BW, and yolk sac, intestine, and liver weights were determined. On d zero post hatch, 20 chicks from each of the 28 TRT-replicate groups (560 total birds) were placed in corresponding isolated wire-floored battery cages. On a daily basis, from d zero to 14 post hatch, pooled fecal samples from each individual replicate cage were collected for oocyst output determination. There was no significant difference among TRT for HI or chick BW on d 21.5 of incubation. In the noninjected control and vaccine-treated groups, mean HI was 93.1 and 89.4%, respectively, and chick BW were 43.4 and 43.8 g, respectively. The mean embryonic stage score was 2.09, and 84.8 and 15.3% of in ovo injections were in the amnion and embryo, respectively. Oocyst shedding began 4 d post hatch (d 6 post injection), and reached a peak at d 7 post hatch (d 10 post injection). It was concluded that the in ovo injection of Inovocox EM1 vaccine did not have a significant detrimental effect on broiler embryogenesis or hatching chick quality.
INTRODUCTION
The conventional post-hatch methods of vaccination such as s.c injection, or spray, drinking water, and feed applications may result in a lack of consistent vaccine delivery and subsequent poor vaccine efficacy. Where possible, these methods are being replaced by in ovo injection technology, which is a faster, more effective, and uniform method of vaccine delivery (Williams, 2007) . Hatchery-applied vaccines for Marek's disease virus (MD), infectious bursal disease virus, and coc-cidiosis can be administered to late-stage chicken embryos via in ovo injection (Jochemsen and Jeurissen, 2002; Weber and Evans, 2003) . The in ovo vaccination of broiler hatching eggs occurs widely in commercial hatcheries in North America, South America, Europe, and Asia (Jochemsen and Jeurissen, 2002) . Coccidiosis is considered as one of the top diseases of concern to the broiler industry worldwide. Avian coccidiosis is a parasitic disease of poultry caused by protozoan parasites of the genus Eimeria (phylum Apicomplexa). Eimeria infects the intestinal tract and is transmitted between birds by a fecal-oral route. Annual economic losses to the commercial poultry industry due to coccidiosis are estimated at $800 million worldwide, and $127 million in the United States. (Chapman, 2009 ). These losses include costs incurred by in-feed medication, mortality, poor feed efficiency, and impaired performance (Williams, 1998) .
In the United States, the coccidiosis vaccine has become widely used as a means of controlling coccidiosis in broiler chickens. Coccidiosis vaccines are used as alternatives to chemotherapeutic agents or as part of a 541 rotation program in combination with other anticoccidial programs, depending on the season of the year (Chapman, 2000) . The Inovocox EM1 (EM1) vaccine (Zoetis Inc., Kalamazoo, MI) contains live oocysts of 3 common species of coccidia: Eimeria acervulina, E. maxima, and E. tenella. The EM1 vaccine is recommended for in ovo vaccination of late stage [18 to19 d of incubation (doi)] embryonated chicken eggs for the prevention of coccidiosis caused by these 3 species of coccidia. The success of in ovo vaccination and the subsequent efficacy of the vaccine are influenced by the application technique used, the timing of the injection relative to the stage of embryonic development, and the exact site of injection (SOI) of the vaccine in the developing embryo. An in ovo vaccination technique must be easy to apply, achieve vaccine efficacy, support embryo health, and ensure chick quality (Williams and Zedek, 2010) . The timing of in ovo injection must be in synchrony with the stage of embryonic development in order to achieve the desired vaccine outcome. The stage of development that is most appropriate is one that allows for the targeted embryonic sites to become optimum in size and position for precise and accurate injection. This typically occurs at the late stages of embryonic development that are associated with the growth and maturation of organ systems formed during the early and mid stages of development.
Although several methods of staging chicken embryonic development have been described (Tong et al., 2013) , the use of embryonic developmental stage scores (ES) provides a more practical, field-based approach that can be used to determine embryonic physiological development. The ES system utilizes predictable physiological markers and developmental features to generate an additive score that ranges from 1 to 7, depending on the stage of embryonic development (unpublished data, Embrex SOP #EMB-007, "Site of Injection and Staging Embryos"). This ES can then be used as a predictable marker for determining the age of the chicken embryo. The age and stage of development of the embryo are important in determining the most probable SOI and the subsequent efficacy of the vaccine. The SOI can occur in 5 different locations in the egg of the developing late stage embryo. These areas are the air cell (AC), amnion (AM), allantois (AL), embryo body (EM), and the yolk sac (YS). The injection of vaccines into any of these compartments within the egg may influence embryo survival, and its response to the vaccine (Williams, 2007) . A precise and accurate SOI of the vaccine is needed in order to obtain an optimal response by the embryo (Williams and Hopkins, 2011) .
Information on the effects of the in ovo injection of the commercial EM1 vaccine on chicken embryos during late stage incubation, and on subsequent hatching chick quality is limited in the scientific literature. A more precise and practical approach for evaluating the success of in ovo injection under commercial hatchery settings is also currently unavailable. Therefore, the objective of this study was to investigate effects of the commercial EM1 vaccine on the hatchability and chick quality variables of broilers injected as embryos at 18.5 doi, and to provide a practical stepwise approach for evaluating the outcome of in ovo coccidiosis vaccination under commercial hatchery practice.
MATERIALS AND METHODS

General
This study was conducted under a protocol that was approved by the Institutional Animal Care and Use Committee of Mississippi State University. A total of 2,520 Ross × Ross 708 broiler hatching eggs collected from a single 48-week-old commercial broiler breeder flock was held for 2 d under standard storage conditions and then individually weighed before being set. A total of 1,764 eggs that were of good quality and within ±10 % of the mean weight of all eggs weighed (60 ± 6.0 g) was randomly set in a Jamesway model PS 500 R setter unit (Jamesway Incubator Company Inc., Cambridge, Ontario, Canada) (Pulikanti et al., 2012) . The eggs were randomly assigned to 28 treatment (TRT)-replicate groups. There were 4 TRT groups, each containing 63 eggs, on each of 7 incubator tray levels. Each tray level served as a replicate unit (experimental block). At 16 doi, eggs were candled as specified by Ernst et al. (2004) , and eggs with cracked shells and those that were unfertilized or contained dead embryos were removed and discarded. After candling, a total of 1,594 embryonated eggs was retained, with approximately 56 eggs belonging to each of the 28 TRTreplicate groups in the setter. All eggs were incubated under standard conditions (Peebles and Brake, 1987) .
Injection and experimental design
On 18.5 doi, eggs were injected with the EM1 vaccine using a commercial Embrex Inovoject multi-egg injection system (Embrex Inovoject R M, Pfizer Inc., Durham, NC) capable of simultaneously injecting a tray of 42 eggs. The EM1 vaccine contains live oocysts of 3 Eimeria spp.: Eimeria acervulina, E. maxima, and E. tenella, diluted as directed by the manufacturer. In order to achieve the manufacturer's vaccination recommendation, each vial of the EM1 vaccine containing 8,000 doses was reconstituted in 400 mL of sterile commercial MD vaccine diluent (Merial Co., Duluth, GA) and administered at the rate of 50 μL per egg. Each dose of the vaccine contained 150 oocysts of a single strain each of E. acervulina and E. tenella, and 75 oocysts of a single strain of E. maxima (total of 375 oocysts per dose). During the injection process, 50 μL vaccine samples were collected directly from the injection needle into a quality control plate, and were then placed in vials and transported in cold conditions to the laboratory for confirmation of oocyst numbers in each dose of vaccine. Also during the injection process, each egg was subjected to one of the following TRT: non-injected (TRT 1), dry-punch (TRT 2), diluent-injected [TRT 3 (50 μL of commercial diluent)], and EM1 vaccine-injected [TRT 4 (50 μL of commercial diluent containing EM1 vaccine)]. Eggs belonging to the non-injected control group were subjected to the same procedures as the other TRT groups, except that they were not injected. Following the completion of the entire injection process, all eggs were subsequently transferred to a Jamesway model PS 500 hatcher unit (Jamesway Incubator Company Inc., Cambridge, Ontario, Canada) (Pulikanti et al., 2012) , in which eggs in their respective TRT replicate groups were assigned to a hatcher basket that corresponded to their positions in the setter.
Site of injection validation
During the in ovo injection process on 18.5 doi, a total of 120 embryonated eggs was injected with coomassie brilliant blue G-250 (colloidal) dye. The dye was injected along with the EM1 vaccine using 2 designated injection lines on the Embrex Inovoject System. The concurrent in ovo injection of the dye with the EM1 vaccine was used to validate the localization of the vaccine by evaluating the location of the dye within the injected embryonated eggs. The SOI and ES of each embryonated egg were subsequently determined following the injection on 18.5 doi.
Evaluation of somatic characteristics, embryo staging, and site of injection
On zero doi, individual set egg weights were recorded. On 21.5 doi (d of hatch), hatchability of injected eggs (HI) and hatching BW were determined. Mean HI and hatching BW were obtained for each of the 28 TRT-replicate groups. Furthermore, on d of hatch, 3 chicks from each TRT-replicate group (84 total) were euthanized, weighed, and necropsied for intestine, YS, and liver extraction. Absolute BW and yolk-free BW, and intestine, YS, and liver weights were determined for each individual chick. Subsequently, intestine, YS, and liver weights relative to BW, and intestine and liver weights relative to yolk-free BW were calculated. Similarly, chick yolk-free body mass and BW relative to set egg weight were calculated. All relative values were expressed as percentages. Yolk-free body mass was calculated by dividing yolk-free BW by BW, and was also subsequently expressed as a percentage. Hatch residue analysis was conducted according to the procedures of Ernst et al. (2004) to determine postinjection embryonic mortality. Only embryos that were observed to have died after injection on 18.5 doi were included in the determination of post-injection embryonic mortality.
Embryo euthanization and SOI evaluation were conducted according to methods described by Williams and Hopkins (2011) . Following the injection of dye, test eggs were retained in their incubation flats and were placed in air-tight bags according to TRT. Embryos contained in their shells were euthanized using CO 2 gas, and were then stored at 4
• C for 4 hours. After euthanization, each egg was carefully dissected to determine its SOI (dye deposition site) and ES. Only normally developed embryos were included in the determination of SOI and ES. The SOI of each egg was designated as either AC, AM, AL, or EM, with EM injections subdivided into i.m and s.c injection groups. The correct SOI for optimal EM1 vaccine efficacy were those that delivered vaccine into the AM (Jochemsen and Jeurissen, 2002; Williams, 2007) or i.m (Williams and Hopkins, 2011) . For the evaluation of ES, various developmental features were assigned respective scoring system values as follows: Internal pip -0 or 1; external pip -0 or 1; head of the embryo located on its right side -0 or 1, with 0 being absent and 1 being present. Furthermore, yolk absorption was scored from 1 to 4: 1 = intestine joined to a full YS via the yolk stalk; 2 = no yolk stalk present and the YS bi-lobed in shape; 3 = YS loses its bi-lobed shape; and 4 = yolk is completely absorbed and there is no discernible shape. The ES scores were additive, with a maximum score of 7. For example, if an embryo had a score of 1 for internal pip, 1 for external pip, 1 for head to the right, and a score of 2 for yolk absorption, this amounted to an ES of 5 out of 7. The higher the ES, the more advanced was embryonic development. In general, by evaluating embryonic developmental features (ES), it is possible to determine the approximate physiological age of the embryo at the time of in ovo injection, and subsequently to determine the success of the in ovo injection.
Chick placement and determination of oocyst output
At hatch, 20 chicks from each of the 28 TRT-replicate groups were weighed and placed in isolated wire-floored battery cages and given feed and water ad libitum for 14 days. The diet used met or exceeded National Research Council (1994) requirements for broiler chickens. Chicks used in all experiments were straight-run. From d zero to 14 post hatch, the entire (pooled) fecal output of all the birds in each individual pen was collected daily. The determination of oocysts per g of feces was performed by centrifugal flotation method as previously described by Ryley et al. (1976) and Weber and Evans (2003) . Briefly, approximately 2 g of feces were placed in a plastic cup and mixed with an amount of water equivalent to approximately 6 × the volume of feces and homogenized into a suspension using a hand-held spatula. The homogenized suspension was poured into a 15 mL centrifuge tube, and, if needed, water was added to bring the volume to approximately 15 mL. The mixture was centrifuged for 8 min at 1,000 × g, the supernatant was poured off, and the pellet was retained in the tube. The supernatant was then discarded and the process was repeated for a second wash. The final pellet was re-suspended in sugar flotation solution (Seather's sugar solution) to increase the specific gravity of the Table 1 . Mean BW, yolk-free BW (YFBW), intestine weight (IW), liver weight (LW), yolk sac weight (YSW), and yolk-free body mass (YFBM) on d zero post hatch in the non-injected, dry-punch, and diluent-injected control eggs, and eggs injected with EM1 vaccine. 
Statistical description
A randomized complete block design was used, with each of the 7 tray levels of the setter and each of the 7 hatching basket levels in the hatcher representing a block. All 4 TRT groups were randomly arranged and represented within each level (block). All variables were analyzed using the MIXED procedure of SAS software 9.4 (SAS Institute Inc., 2012). Treatments were viewed as fixed effects and blocks as random effects. A one-way ANOVA was used to analyze TRT differences for all the variables investigated. Least-square means were compared in the event of significant global effects. Global and least-square means differences were considered significant at P ≤ 0.05.
RESULTS
There were no significant TRT effects on HI (P = 0.08) or hatching BW (P = 0.43) at 21.5 doi. However, HI at 21.5 doi in the non-injected control group was numerically higher compared to that in the diluent-injected control and the vaccine-injected treatment groups. The HI means in the non-injected, dry punch, diluent-injected, and vaccine-injected treatment groups were 93.1, 91.7, 90.6, and 89.4%, respectively (pooled SEM = 0.98 %). The hatching BW means in the non-injected, dry punch, diluent-injected, and vaccine-injected treatment groups were 43.4, 43.8, 43.8, and 43.8 g, respectively (pooled SEM = 0.23 g). Similarly, there were no significant TRT effects on any of the other hatching chick quality variables evaluated in this study. Nevertheless, the TRT means for absolute and yolk-free BW; absolute intestine, liver, and YS weight; and yolk-free body mass are provided in Table 1 for observation. The TRT means for total and yolk-free BW as percentages of set egg weight; intestine and liver weights as percentages of total and yolk-free BW; and YS weight as a percentage of BW are not shown.
Post-hatch oocyst output following the in ovo injection of the EM1 vaccine is shown in Figure 1 . The oocysts of all 3 species of Eimeria (acervulina, maxima, and tenella) were recovered from fecal samples, confirming that the embryos became infected subsequent to the in ovo injection of the coccidiosis vaccine. Oocyst output was greatest on d 7 post hatch, when embryos received E. acervulina, E. maxima, and E. tenella in ovo on 18.5 doi. This peak was followed by a second, smaller peak at d 10 post hatch. Beginning at d 4 and 5 post hatch, small (approximately 20 × 16 μm) and large (approximately 32 × 28 μm) sized oocysts were observed in the feces of birds that received the EM1 vaccine. Based on the known minimum pre-patent period and size of oocysts, we assumed that small and large sized oocysts were indicative of E. acervulina and E. maxima infection, respectively. Peak oocyst output observed on d 7 post hatch suggests that all Eimeria spp. were present. A second, smaller peak of oocyst output detected by d 10 post hatch suggests that there was a delayed output of oocysts in a few chicks. Chicks hatched from control eggs that received no injection, a drypunch injection, or a diluent injection did not shed a detectable number of oocysts during the 2-week posthatch period. Mean ES for 118 embryonated eggs at 18.5 doi was 2.09 ± 0.43. Furthermore, the SOI evaluation of those same eggs at 18.5 doi indicated that 84.75 and 15.25% of the eggs received vaccine in AM and EM sites, respectively, and within the EM site 6.8 and 8.5% of eggs were injected specifically in i.m and s.c sites, respectively (Table 2) .
DISCUSSION
Following the in ovo injection of the EM1 vaccine, the success of vaccination was further determined by evaluating fecal oocyst recovery from the post-hatch chicks to ensure that the birds vaccinated with the EM1 vaccine actually received vaccinal oocysts by way of in ovo injection. Post-injection oocyst output evaluation indicated that the chicks were in fact infected with all 3 Eimeria spp. when the EM1 vaccine was administered in ovo. Moreover, there were no oocysts in the feces of chicks from the non-injected and diluent-injected control groups. Peak oocyst output was observed at d 7 post hatch (approximately 10 d post injection). This timing of fecal oocyst recovery is consistent with previous work, in which the in ovo injection of oocysts resulted in a shedding peak at approximately 7 d post hatch (Weber and Evans, 2003) . It has been suggested that following an in ovo injection of coccidial oocysts, oocysts may remain inactive in the embryo's intestine after being ingested from the amniotic fluid with no significant life cycle changes occurring until the chicks hatch (Weber et al., 2001) . As with previous studies (Weber et. al., 2004) , the current evidence suggests that infection with EM1 vaccine oocysts could have been established post hatch. This evidence is based on the time that oocysts of E. acervulina (4 d post hatch) and E. maxima (6 d post hatch) were observed in the feces in relation to their known pre-patent life cycle period (Conway and McKenzie, 1991) . Furthermore, histopathological examination conducted on intestinal tissues on d of hatch did not reveal any noticeable coccidia stages for all 3 Eimeria spp. (data not shown). This suggests that chicks may have become infected around the time of hatching or within a few d after hatch, or that the histological techniques employed were not sensitive enough to detect the life cycle stages.
The HI of eggs that were injected with the EM1 vaccine was not significantly affected. Although there was a numerical decrease in HI in the vaccine-injected group, there were also decreases observed in the dry punch and diluent-injected control groups in comparison to the non-injected control group. This numerical A total of 118 embryos were used to calculate the mean ES and SOI.
2 Embryo populations were selected from all treatment groups (non-injected, dry-punch, diluent-injected controls, and EM1 vaccine).
decrease in HI likely resulted in part from the creation of injection holes in the embryonated eggs belonging to these groups (dry punch, diluent-injected, and vaccineinjected groups). However, subjection of embryos in the vaccine-injected group to the Eimeria oocysts may have added to the numerical decrease in HI. Although HI was not significantly affected by EM1 vaccine injection in this study, it does not preclude the likelihood of its causing a significant decrease in HI in commercial settings in which much larger numbers of birds are involved. The imposed TRT had no significant effect on mean chick BW at 21.5 doi. Furthermore, there were no statistical differences between the vaccine-injected and control groups for all the chick quality variables determined in this study. Yolk-free body mass (yolk-free BW divided by BW) is an indicator of chick development during incubation and has been positively correlated with subsequent chick performance (Molenaar et al., 2011) . The in ovo injection of the EM1 vaccine in the current report, therefore, did not adversely affect embryonic development or survivability when assessed at 21.5 doi, and likewise exerted no subsequent negative effects on hatchling quality.
A successful outcome of any in ovo vaccination depends on at least 2 major factors: the stage of embryo development at injection, and the accuracy of vaccine deposition in the appropriate SOI. The stages of embryo development are practically determined by the 3 major phases (early, mid, and late phase), which are classified into embryonic days (ED) based on a 24-hour calendar time period (Tong et al., 2013) . The ES system, however, is a more precise method of evaluating and classifying embryonic development by utilizing physiological markers and developmental features of the embryos that follow a predictable sequence. The ES scoring system utilizes an additive scale that increases with developmental maturation to a maximum of 7. The points are added when specific criteria are met as the embryo develops towards hatching (unpublished data, Embrex SOP #EMB-007, "Site of Injection and Staging Embryos"). Embryos with a high ES are more developed than are embryos with a low ES. The ES is a predictor of the actual physiological age of an embryo and is influenced by factors such as incubation time and conditions, flock breed and genetics, and maternal nutrition. Accurate information regarding embryonic development is important for SOI accuracy and eventual vaccine efficacy.
Previous extensive work conducted on in ovo vaccination under commercial standard practice (Williams and Zedek, 2010; Williams and Hopkins, 2011) suggests that the deposition of in ovo-injected vaccine in the appropriate location is critical for the protective efficacy of the vaccine against MD. Five regions of embryonated eggs that are primarily involved with in ovo injection include the AC, AL, AM, EM, and YS (Wakenell, et al., 2002; Williams and Zedek, 2010) . The EM region can be further divided into s.c, i.m, intra-cranial, intra-orbital, or intra-abdominal regions (Williams and Zedek, 2010) . Wakenell et al., (2002) , confirmed that application of MD vaccine at ED 18.0 through the intraembryonic route provided protection equal to delivery through the amniotic route. In addition, targeting vaccination between ED 18.0 and 19.0 will ensure delivery into the AM or the embryo. On the contrary, delivery into the AC, AL, intra-cranial, intra-orbital, or intra-abdominal regions is regarded as unsatisfactory vaccine delivery, and will lead to an ineffective vaccination and possibly the death of the embryo (Wakenell, et al., 2002; Williams and Zedek, 2010) . Based on the oocyst shedding result in this study, it is evident that both the AM and embryonic route (i.m and s.c) appear to be efficacious for in ovo injection of the EM1 vaccine. Vaccines or other solutions deposited in the AM are imbibed or aspirated by the embryo prior to hatching (Jochemsen and Jeurissen, 2002) . With the EM route of administration, we speculate that either the embryo swallows the vaccine that leaked into the AM, that is the uptake of residual oocysts during preening at a late stage of embryonic life, or there is the transfer of oocysts through the vascular system producing a humoral response to the vaccine.
In a previous study (unpublished data) in which the relationship between ES and SOI was evaluated, it was shown that when ES was between 1 and 3, there was an 80 to 94% chance of vaccine deposition in the AM and a 6 to 20% chance of deposition in the EM. Another earlier study (unpublished data) was conducted to show the relationship between ES and embryonic age at ED 17.5, 18.0, 18.5, and 19.0, using eggs from 6 flocks of 3 breed crosses (5,341 total eggs) that were set in a Jamesway incubator at different times. The results showed that there was a significant (P ≤ 0.05) distribution of ES values across all 4 ED. In brief, ED 17.5, 18.0, 18.5, and 19.0 corresponded to ES 1, 2, 3, and 4, respectively, in approximately 60% of the embryo population. Based on these results, the ES and SOI results in this study showed that the embryos were at a physiological stage of development that corresponded to ED 18.2 and a 100% success rate of vaccine delivery (84.75% AM and 15.25% EM). Vaccine deposition in the AM or EM (i.m or s.c of the right breast area) of the developing embryo is the target site for optimal uniform EM1 vaccination. The physiological markers for these embryos at ED 18.0 and 18.5 were: head at the right wing, internal pip may be present or absent, external pip is absent, and with yolk absorption scores between 1 and 2. This stage of physiological development corresponds to a time that is recommended for injection of the EM1 vaccine for optimal vaccine delivery and subsequent vaccine uptake by the embryo.
In conclusion, the in ovo injection of the EM1 vaccine on 18.5 doi in Ross × Ross 708 broilers had no detrimental effect on hatching chick quality. It also did not significantly affect embryonic survivability, as evidenced by the lack of significant treatment effects on HI. Furthermore, the injection of the EM1 vaccine produced a vaccine-induced infection that was made evident by counts of the number of oocysts per g of feces occurring between one and 14 d post hatch in the vaccine-injected group. The use of qualitative procedures, namely SOI and ES, ensured that the injection of the EM1 vaccine between 18 and 18.5 doi provided accurate delivery of the vaccine into the AM and EM, and the recovery of oocysts during the post-hatch period could provide the stimulation of immunity necessary for protection against coccidial challenges.
